Call us now0755-8668-0658 E-mailinfo@immuclin.com

Intorduction

Lung Cancer

 Lung cancer is one of the malignant tumors with the fastest increase in morbidity and mortality and the greatest threat to people's health and life. In the past 50 years, many countries have reported that the incidence and mortality of lung cancer have increased significantly. The incidence and mortality of lung cancer in men are the first of all malignant tumors, the incidence of women is the second, and the mortality is second. The cause of lung cancer is still not completely clear. A large amount of data shows that long-term heavy smoking is very closely related to the occurrence of lung cancer. Existing studies have shown that the probability of long-term large numbers of smokers suffering from lung cancer is 10-20 times that of non-smokers. The younger the age at which smoking begins, the higher the probability of developing lung cancer. In addition, smoking not only directly affects my health, but also has a negative impact on the health of the surrounding people, leading to a significant increase in the prevalence of lung cancer among passive smokers. The incidence of lung cancer among urban residents is higher than that in rural areas, which may be related to urban air pollution and carcinogens contained in smoke and dust. Therefore, we should promote non-smoking and strengthen urban environmental sanitation.

Fever, weight loss and cachexia



Chest pain, chest tightness, shortness of breath


Symptoms

cough

Blood in sputum or hemoptysis

Fever, weight loss and cachexia



Chest pain, chest tightness, shortness of breath


ACTL Treatment Plan

After determining the indications for ACTL treatment of patients in accordance with the "Screening Criteria for Cancer Patients", the specific ACTL treatment plan should be determined according to the specific conditions of the patient, such as the patient's condition, receiving radiotherapy and chemotherapy, and the following principles should be mastered:

1. The patient should have blood routine, liver and kidney function, relevant serum tumor markers (tumor antigen or tumor-related antigen) laboratory test and imaging examination results.

2. During ACTL treatment, in addition to treatments that damage immune function or bone marrow suppression, patients can receive other anti-tumor treatments.

3. The number of antigen-specific cytotoxic T Iymphocytes (CTL) of patients who are reinfused in each treatment should be ≥1*108

4. For patients with allergies or elderly and infirm, when CTL is reinfused, a small dose of dexamethasone can be considered.

5. Clinical therapeutic grade interleukin 2 (IL-2): At the same time as CTL is reinfused, intravenous infusion of IL-2 is recommended to adjust the patient's immune function, prolong the activity of CTL in the body, and improve the efficiency of killing tumor cells. For the first reinfusion, the recommended dose is 500,000 units to observe the patient's tolerance to IL-2. If the patient has no obvious adverse reactions or allergic reactions, from the second ACTL treatment, 1 to 2 million units of IL-2 will be given each time CTL is infused. It is not recommended to use my country's SFDA approved for clinical treatment

After determining the indications for ACTL treatment of patients in accordance with the "Screening Criteria for Cancer Patients", the specific ACTL treatment plan should be determined according to the specific conditions of the patient, such as the patient's condition, receiving radiotherapy and chemotherapy, and the following principles should be mastered:

1. The patient should have blood routine, liver and kidney function, relevant serum tumor markers (tumor antigen or tumor-related antigen) laboratory test and imaging examination results.

2. During ACTL treatment, in addition to treatments that damage immune function or bone marrow suppression, patients can receive other anti-tumor treatments.

3. The number of antigen-specific cytotoxic T Iymphocytes (CTL) of patients who are reinfused in each treatment should be ≥1*108

4. For patients with allergies or elderly and infirm, when CTL is reinfused, a small dose of dexamethasone can be considered.

5. Clinical therapeutic grade interleukin 2 (IL-2): At the same time as CTL is reinfused, intravenous infusion of IL-2 is recommended to adjust the patient's immune function, prolong the activity of CTL in the body, and improve the efficiency of killing tumor cells. For the first reinfusion, the recommended dose is 500,000 units to observe the patient's tolerance to IL-2. If the patient has no obvious adverse reactions or allergic reactions, from the second ACTL treatment, 1 to 2 million units of IL-2 will be given each time CTL is infused. It is not recommended to use my country's SFDA approved for clinical treatment

After determining the indications for ACTL treatment of patients in accordance with the "Screening Criteria for Cancer Patients", the specific ACTL treatment plan should be determined according to the specific conditions of the patient, such as the patient's condition, receiving radiotherapy and chemotherapy, and the following principles should be mastered:

1. The patient should have blood routine, liver and kidney function, relevant serum tumor markers (tumor antigen or tumor-related antigen) laboratory test and imaging examination results.

2. During ACTL treatment, in addition to treatments that damage immune function or bone marrow suppression, patients can receive other anti-tumor treatments.

3. The number of antigen-specific cytotoxic T Iymphocytes (CTL) of patients who are reinfused in each treatment should be ≥1*108

4. For patients with allergies or elderly and infirm, when CTL is reinfused, a small dose of dexamethasone can be considered.

5. Clinical therapeutic grade interleukin 2 (IL-2): At the same time as CTL is reinfused, intravenous infusion of IL-2 is recommended to adjust the patient's immune function, prolong the activity of CTL in the body, and improve the efficiency of killing tumor cells. For the first reinfusion, the recommended dose is 500,000 units to observe the patient's tolerance to IL-2. If the patient has no obvious adverse reactions or allergic reactions, from the second ACTL treatment, 1 to 2 million units of IL-2 will be given each time CTL is infused. It is not recommended to use my country's SFDA approved for clinical treatment

  • I. Patients with stage II tumors

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

  • III. Patients with stage IV tumors

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

  • Patients who have finished radiotherapy and chemotherapy

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

  • Patients receiving radiotherapy and chemotherapy

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

  • Patients with severe disease and rapid progress

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are ready to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

    1. Patients who are receiving radiotherapy and chemotherapy are not recommended to receive ACTL treatment at the same time;

    2. For patients who are going to receive radiotherapy or chemotherapy, consider the following ACTL treatment plan, but pay attention to the obvious decline in the number of white blood cells or bone marrow suppression, and stop ACTL treatment;

ACTL Case Studies

Expert Consultation